Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae050 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Melissa Hardy und 5 weiteren Autor:innen. Beteiligte Einrichtung: UQ Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Meropenem, Piperacillin, Tazobactam Drug Combination, Anti-Bacterial Agents, Klebsiella pneumoniae. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of Queensland.
Abstract (Originalsprache)
Background
Clinical trials of treatments for serious infections commonly use the primary endpoint of all-cause mortality. However, many trial participants survive their infection and this endpoint may not truly reflect important benefits and risks of therapy. The win ratio uses a hierarchical composite endpoint that can incorporate and prioritize outcome measures by relative clinical importance.
Methods
The win ratio methodology was applied post hoc to outcomes observed in the MERINO trial, which compared piperacillin-tazobactam with meropenem. We quantified the win ratio with a primary hierarchical composite endpoint, including all-cause mortality, microbiological relapse, and secondary infection. A win ratio of 1 would correspond to no difference between the 2 antibiotics, while a ratio <1 favors meropenem. Further analyses were performed to calculate the win odds and to introduce a continuous outcome variable in order to reduce ties.
Results
With the hierarchy of all-cause mortality, microbiological relapse, and secondary infection, the win ratio estimate was 0.40 (95% confidence interval [CI], .22–.71]; P = .002), favoring meropenem over piperacillin-tazobactam. However, 73.4% of the pairs were tied due to the small proportion of events. The win odds, a modification of the win ratio accounting for ties, was 0.79 (95% CI, .68–.92). The addition of length of stay to the primary composite greatly minimized the number of ties (4.6%) with a win ratio estimate of 0.77 (95% CI, .60–.99; P = .04).
Conclusions
The application of the win ratio methodology to the MERINO trial data illustrates its utility and feasibility for use in antimicrobial trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UQ Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.
- Central Microbiology Laboratory, Pathology Queensland, Brisbane, Queensland, Australia.
- ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
- Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom.
- Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
ORCID-Profile: David L Paterson
Förderung
- University of Queensland
Zitieren
APA
Hardy, M., Harris, P. N. A., Paterson, D. L., Chatfield, M. D., Mo, Y., & MERINO Trial Investigators (2024). Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae050
Vancouver
Hardy M, Harris PNA, Paterson DL, Chatfield MD, Mo Y, MERINO Trial Investigators. Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae050
BibTeX
@article{Hardy2024,
author = {Hardy, Melissa and Harris, Patrick N A and Paterson, David L and Chatfield, Mark D and Mo, Yin and MERINO Trial Investigators, MERINO Trial Investigators},
title = {Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae050}
}
EUVIMED